CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.License Agreement • February 22nd, 2024 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • Massachusetts
Reference is hereby made in this letter agreement (this “Letter Agreement”) to that certain License Agreement by and between Novartis International Pharmaceutical Ltd. (“Novartis”) and QED Therapeutics, Inc. (“QED”) dated as of January 29, 2018 (as originally executed and as the same may be amended, supplemented or modified from time to time in accordance with its terms, the “License Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the License Agreement. Novartis and QED are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Employment Agreement • February 22nd, 2024 • BridgeBio Pharma, Inc. • Pharmaceutical preparations
This letter (this “Amendment”) confirms the agreement between you and BridgeBio Services, Inc. (the “Company”) to amend the terms of the employment agreement between you and the Company effective October 28, 2018 (the “Employment Agreement”), to provide a cash severance opportunity upon certain types of terminations of your employment with the Company. Capitalized terms not otherwise defined herein shall have the respective meanings ascribed to such terms in the Employment Agreement.
